The strong Q1 beat and rapid early adoption of IMCIVREE in acquired HO (150+ patient start forms in 6 weeks) signal accelerating commercial traction. Watch for upcoming catalysts: Phase 2 PWS data (Q2 2026), RM-718 data (mid-2026), and Japan PMDA decision (H2 2026). The stock has historically underperformed post-earnings (avg T+20 -5.82% on prior reports), but this beat is more substantive than prior neutral filings.
Price Chart
Executive Summary
Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M, beating the $56.1M consensus, and an EPS loss of -$0.73, beating the -$0.86 estimate by 15.2%. The beat was driven by strong IMCIVREE sales, including the newly approved acquired hypothalamic obesity indication, but the company's net loss widened to -$56.7M from -$50.8M a year ago, and operating expenses surged 41% YoY.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $60.1M vs consensus $56.1M (beat)
- Q1 2026 EPS -$0.73 vs consensus -$0.86 (15.2% beat)
- IMCIVREE approved by FDA for acquired hypothalamic obesity on March 19, 2026; >150 patient start forms received in first 6 weeks
- European Commission granted Marketing Authorization for IMCIVREE in acquired HO on May 1, 2026
- Net loss widened to -$56.7M from -$50.8M YoY; operating expenses rose to $112.5M from $79.7M
- Cash position $340.6M as of March 31, 2026; company expects sufficient runway for at least 24 months
- Non-GAAP operating expense guidance for FY2026: $385M-$415M
Financial Impact
Revenue beat of $4.0M (7.1%) vs consensus; EPS beat of $0.13 (15.2%) vs consensus; net loss widened by $5.9M YoY
Risk Factors
- Operating expenses growing faster than revenue (41% YoY vs 59% revenue growth)
- EMANATE Phase 3 trial missed primary endpoint in March 2026, creating pipeline uncertainty
- Sequential U.S. revenue declined 5% QoQ due to inventory and insurance transitions
- High cash burn rate ($48.3M in Q1 2026) despite $340.6M cash position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287506 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 144 | $96.77 $99.27 | ▼ −2.58% | ▼ −0.47% | $93.68 (+3.19%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▲ +1.65% | ▲ +1.45% | $93.68 (+18.72%) |
Aug 17, 2026 6w ago | Insider Cluster | $115.25 $113.35 | ▼ −1.65% | ▼ −1.45% | $93.68 (−18.72%) |
Aug 4, 2026 8w ago | 8-K | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Aug 4, 2026 8w ago | Press Release | $105.78 $112.85 | ▲ +6.68% | ▲ +6.78% | $93.68 (−11.44%) |
Jul 8, 2026 12w ago | Press Release | $115.48 $106.09 | ▼ −8.13% | ▼ −8.00% | $93.68 (−18.88%) |
Jun 22, 2026 14w ago | 144 | $106.19 $110.04 | ▲ +3.63% | ▲ +2.61% | $93.68 (−11.78%) |
Jun 15, 2026 15w ago | 8-K | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 15, 2026 15w ago | Press Release | $89.72 $106.19 | ▲ +18.36% | ▲ +20.59% | $93.68 (+4.41%) |
Jun 13, 2026 15w ago | Press Release | $89.70 $101.39 | ▲ +13.03% | ▲ +14.42% | $93.68 (+4.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access